Articles from ClearNote Health

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced a lineup of presentations at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin taking place October 17-21, 2025. Meeting attendees can review the following presentations to learn about ClearNote Health’s innovative early cancer detection technology and latest clinical research success.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that it has received a United Kingdom Conformity Assessed (UKCA) marking for its Avantect® Multi-Cancer Detection Test and Avantect® Ovarian Cancer Test. Part of the UK’s independent product safety framework following its departure from the European Union, this designation confirms compliance with UK medical device regulations and is a prerequisite for selling products in the UK. The company’s Avantect Pancreatic Cancer Test received the same certification in July 2025.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that it has received UK Conformity Assessed (UKCA) marking for its Avantect® Pancreatic Cancer Test. The UKCA mark, established as part of the United Kingdom’s independent product safety regulatory framework following its departure from the European Union, signifies compliance with UK medical device regulations and paves the way for commercial availability in the UK market.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced initiation of patient enrollment for a landmark clinical study utilizing its Avantect® Pancreatic Cancer Test. Sponsored by University Hospital Southampton NHS Foundation Trust, the prospective, multicenter study seeks to improve early detection of pancreatic cancer in individuals recently diagnosed with type 2 diabetes. With up to 15,000 patient participants, it will be the largest study of its kind.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced a lineup of presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago taking place April 25-30, 2025. Meeting attendees can learn about ClearNote Health’s innovative early cancer detection technology and latest clinical research success.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced an agreement with Claritev, Inc. (“Claritev”) (NYSE: CTEV), previously MultiPlan, Inc. (NYSE: MPLN), a technology and data insights company focused on making healthcare more affordable, transparent, and fair for all. As part of the agreement, ClearNote Health’s Avantect® Pancreatic Cancer Test will now be available to health plan members accessing Claritev’s national PHCS and MultiPlan Networks.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved its Avantect® Pancreatic Cancer Test. With this approval, clinicians in New York State can now order this highly sensitive blood test, which is designed to detect the biological signals of pancreatic cancer in its earliest stages for patients with known risk factors.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced that its Avantect® Multi-Cancer Detection Test was selected for the Vanguard Study funded by the National Cancer Institute (NCI), part of the National Institutes of Health. The Avantect Multi-Cancer Detection Test was one of two tests selected after a thorough evaluation of emerging multi-cancer detection technologies. The Vanguard Study aims to address the feasibility of using targeted multi-cancer detection tests in randomized controlled trials (RCTs) designed to assess the clinical benefit of cancer detection, possibly in the early stages, through noninvasive blood tests.

ClearNote Health, a company focused on improving early detection for some of the deadliest cancers, today announced a new collaboration with research teams in Southampton in the United Kingdom. Researchers at the Southampton Clinical Trials Unit, based at the University of Southampton, will use the ClearNote Health Avantect® Pancreatic Cancer Test in a landmark study, sponsored by University Hospital Southampton NHS Foundation Trust, that builds on the well-established relationship between pancreatic cancer and type 2 diabetes. The prospective, multicenter study will be the largest of its kind, including up to 15,000 patient participants recently diagnosed with type 2 diabetes.

ClearNote Health, an early cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the results of a cost-effectiveness analysis on the use of the Avantect Pancreatic Cancer test to manage new-onset diabetes (NOD) patients for their risk of developing pancreatic cancer in the first three years post diabetes diagnosis. These findings, developed in collaboration with the Mayo Clinic and the Arizona Centers for Digestive Health, will be presented on November 19 at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) conference.

ClearNote Health, an early cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for the Avantect Ovarian Cancer Test. Effective October 1, 2024, the new CPT code, 0507U, establishes a reimbursement pathway for increased patient access and broader test adoption. The Avantect test is intended for patients at high risk for ovarian cancer, such as those with a genetic predisposed risk such as BRCA1, BRCA2, a family history of ovarian cancer, or a personal history of breast cancer before age 40.

ClearNote® Health, a company on a mission to enable longer lives for people with cancer through earlier detection, today announced results from a collaboration study with Novartis and the Norwegian Biobank assessing plasma-based epigenetic biomarkers associated with response to treatment with Lutathera® ([177Lu]Lu-DOTA-TATE) in patients with pancreatic neuroendocrine tumors.

ClearNote® Health, a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the publication of new data from a study demonstrating the applications of its epigenomic technology platform in predicting and monitoring immunotherapy responses for patients with non-small cell lung cancer (NSCLC). The article, “Plasma Cell-Free DNA Hydroxymethylation Profiling Reveals Anti-PD-1 Treatment Response and Resistance Biology in Non-Small Cell Lung Cancer,” was published in the online issue of The Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC).

ClearNote® Health, a company with a mission to enable longer lives for people with cancer through earlier detection and empowering biopharmaceutical companies in developing better drugs, today announced it has entered into a collaboration with Bayer to evaluate biological mechanisms underlying patient response and resistance to treatments for metastatic hormone-sensitive prostate cancer. The companies will apply ClearNote Health’s epigenomic cancer detection platform to liquid biopsy samples to monitor patient response to prostate cancer therapies. The collaboration aims to provide a deeper understanding of disease biology to help advance Bayer’s precision medicine programs in prostate cancer.

ClearNote® Health, a cancer detection company focused on identifying cancer earlier in people at high risk for the deadliest cancers to enable longer lives, today announced it has signed an agreement to partner with the Pancreatic Cancer Early Detection (PRECEDE) Consortium. The PRECEDE Consortium is an international, multi-institutional collaborative group of experts working to improve early detection for those with a heritable risk for pancreatic cancer, or those with pancreatic cysts, through a novel model of collaboration and data sharing.

ClearNote Health™, a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code for the Avantect™ Pancreatic Cancer Test. Effective October 1, 2023, the new CPT code, 0410U, establishes a reimbursement pathway for increased patient access and broader test adoption. The Avantect test is intended for patients at high risk for pancreatic cancer, such as those recently diagnosed with Type 2 diabetes or with a family history of pancreatic cancer.

ClearNote Health™, a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer, healthier lives, today announced the publication of its analytical validation study for the Avantect™ Pancreatic Cancer Test in Clinical Gastroenterology and Hepatology. Data from the study, “Epigenomic Blood-based Early Detection of Pancreatic Cancer Employing cell-free DNA,” showed robust performance of the Avantect test in the detection of pancreatic cancer in high-risk patients, such as those recently diagnosed with Type 2 diabetes. These new data support the use of ClearNote Health’s epigenomic platform in effectively identifying cancer presence in individuals at higher risk for pancreatic cancer, thereby facilitating timely disease detection and intervention.

ClearNote Health™ (formerly known as Bluestar Genomics), a cancer detection company focused on enabling people at risk for high-mortality cancers to live longer healthier lives, today announced that Chief Executive Officer Dave Mullarkey will present a company update at the 41st annual J.P. Morgan Healthcare Conference on Wednesday, January 11 at 2:30 p.m. PST. Mullarkey will discuss the company’s ongoing clinical validation and commercialization efforts across a multi-test portfolio. The Avantect™ early cancer detection portfolio includes the recently launched test for pancreatic cancer, available now for physician ordering in patients over 50 with Type 2 diabetes diagnosed in the past three years.

Bluestar Genomics today announced the company’s U.S. and international commercialization of its first test for early detection of pancreatic cancer in high-risk patients, and unveiled a new name, ClearNote Health™. The company also announced its first international distribution agreement with LifeStrands Genomics, a part of Pathology Asia’s Genomics and Life Sciences division.